Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 3, 2026

Stock market today: Dow, S&P 500, and Nasdaq slide as oil rises amid war worries

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, and Nasdaq slide as oil rises amid war worries US stocks declined but came back from deeper losses for the second day in a row on Tuesday after Israel and US jets launched new strikes on Iran, as the widening conflict stoked worries about a drawn-out regional war…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump refused to rule out putting American boots on the ground in Iran

    80% confidence
  • US military operation in Iran projected to last four to five weeks but capable of going far longer

    80% confidence
  • Trump administration will soon roll out program to help mitigate rising energy costs

    80% confidence
  • Until Target starts stacking positive quarters, don't buy the stock and favor Walmart or Costco on pullbacks

    80% confidence
  • The hardest hits are yet to come from the US military in Iran campaign

    80% confidence
  • Trump administration's tariffs have been overwhelmingly borne by US consumers and businesses

    80% confidence
  • US could see a little high oil prices for a little while, but prices will drop lower than before after war ends

    80% confidence
  • Data sources show overall market share was at least flat, pointing to slightly softer customer demand during holiday quarter

    80% confidence
  • Target should stay in penalty box and is a 'prove it' stock

    80% confidence
  • Middle East war will affect near-term inflation outlook and increase economic uncertainty

    80% confidence
  • Best Buy expects first quarter same-store sales to return to growth, rising 1%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com